Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aditxt, Inc. (NASDAQ: ADTX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Aditxt describes its business as a social innovation platform accelerating promising health innovations, as well as its governance, capital structure, and key agreements.
Through Forms 10-K and 10-Q, investors can review Aditxt’s periodic financial statements and management discussions, including information about its programs in immune health, precision diagnostics, autoimmunity, cancer and early disease detection, infectious diseases, and women’s health. When Aditxt files a Form 12b-25 (NT 10-Q), it provides an explanation for delayed quarterly reports and indicates the expected timing of the filing.
Current reports on Form 8-K document material events such as the implementation of a 1-for-113 reverse stock split, amendments to the certificate of incorporation, entry into or termination of material definitive agreements, and financing arrangements. For example, Aditxt has used Form 8-K to report the approval and effectuation of its reverse stock split, the termination of its Amended and Restated Merger Agreement with Evofem Biosciences, Inc., and the issuance of notes and other securities.
Proxy statements on Schedule 14A (such as definitive proxy statements for special meetings) detail proposals submitted to stockholders, including approvals for issuances of common stock underlying various series of convertible preferred stock and warrants, the adoption of an Employee Stock Purchase Plan, amendments to the company’s equity incentive plan, authority to effect a reverse stock split, and a non-binding advisory vote on a proposed name change to “bitXbio, Inc.” These documents also describe meeting logistics and voting procedures.
Investors interested in ownership and governance can review information on security ownership of certain beneficial owners and management within proxy materials, while exhibits to Forms 8-K and other reports may include key agreements, amendments, and certificates of amendment. Stock Titan’s interface surfaces these filings as they appear on EDGAR and can pair them with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand complex items such as capital structure changes, equity plans, and material contracts.
For those tracking insider and security-holder activity, related forms and disclosures filed by Aditxt and its insiders can be viewed alongside the company’s core reports. Together, these filings form the primary regulatory record of how Aditxt presents its strategy, risk factors, and significant corporate actions to the market.
Aditxt, Inc. entered into a financing deal by issuing and selling senior unsecured promissory notes with an aggregate original principal amount of $1,250,000 to accredited investors for a purchase price of $1,000,000, reflecting a $250,000 original issue discount. The Notes bear 10% annual interest, payable monthly, and are scheduled to mature on September 30, 2026. If Aditxt sells common stock through an at-the-market offering or equity line of credit, all such gross proceeds, net of specified expenses, must be used weekly to redeem the Notes at 120% of the amount redeemed. Upon an event of default, holders can require redemption at 125% of the redeemed amount, and a bankruptcy event triggers immediate payment of 125% of all outstanding principal, interest and late charges, alongside restrictive covenants after maturity.
Aditxt, Inc. registers up to 148,278,241 shares of Common Stock for resale by selling stockholders, representing shares issuable upon exercise of outstanding warrants. The registration covers resale on a resale basis by the identified selling holders.
The Company will not receive proceeds from secondary sales; however, if the warrants are exercised for cash at the current $0.50 exercise price, cash proceeds to the Company would be approximately $74.14 million. The prospectus states the company’s Nasdaq closing price on April 2, 2026 was $0.794 per share.
Aditxt, Inc. filed an amended current report to add full financial statements for its acquisition of Ignite Proteomics LLC and related unaudited pro forma consolidated financials. The deal consideration includes 36,000 shares of Series A-2 Convertible Preferred Stock with an aggregate stated value of $36.0 million.
Ignite’s audited results show modest 2025 revenue of $43,539 and a net loss of $5,701,059, leading to a member’s deficit of $6,807,109 and a going concern warning due to recurring losses and negative operating cash flows. Pro forma balance sheets record preliminary goodwill of $36,551 (in thousands of dollars) related to the transaction.
Aditxt, Inc. is calling a virtual 2026 annual meeting on May 1, 2026 at 12:00 p.m. ET, where holders of common stock as of the March 26, 2026 record date, when 861,482 shares were outstanding, can vote online.
Stockholders will vote on six items: electing five directors for one-year terms; ratifying dbbmckennon as independent auditor for 2026; an advisory “say‑on‑pay” vote on executive compensation; an advisory vote on how often to hold say‑on‑pay, with the board recommending every three years; authorizing the board to implement a reverse stock split within one year at a ratio between 1‑for‑2 and 1‑for‑250; and approving the ability to adjourn the meeting if needed.
The proxy details leadership and compensation, including 2025 base salaries of $500,000 for CEO Amro Albanna, $325,000 for Chief Innovation Officer Shahrokh Shabahang, $385,008 for Chief M&A Officer Corinne Pankovcin, and $395,000 for CFO Thomas Farley, plus change‑in‑control severance protections. It also confirms independent board committees, audit fees, and that the reverse split is intended to support Nasdaq listing and broaden investor appeal.
Aditxt, Inc. reports that Nasdaq has determined the company is back in compliance with its continued listing standards under Nasdaq Listing Rule 5550(b)(1). This decision is based on Aditxt’s Form 10-K, which shows stockholders’ equity of $3,953,682, and Nasdaq has closed the matter.
Aditxt, Inc. files its annual report describing a multi-subsidiary biotech platform focused on immune modulation, molecular diagnostics and infectious disease therapeutics, all still in development with no significant commercial revenue. The company reports a net loss of $42,787,043 for 2025 and an accumulated deficit of $209,808,770, raising substantial doubt about its ability to continue as a going concern.
Aditxt highlights Adimune’s ADI-100 immune tolerance candidate moving toward first-in-human trials, Pearsanta’s Mitomic-based cancer and endometriosis tests in development, and newer platforms in antiviral (Adivir) and women’s health (Adifem). The company outlines the now-terminated Evofem merger after multiple amendments, while retaining its Evofem preferred shares and warrants.
The report flags serious Nasdaq listing risks. As of March 30, 2026, Aditxt’s market capitalization is about $713,000, far below both existing equity thresholds and a proposed $5.0M market cap standard that, if adopted, could trigger rapid suspension and delisting without a cure period. Aditxt states its current cash will not fund 12 months of operations and that it must raise additional capital, with uncertainty around availability and terms.
Aditxt, Inc. increased the maximum aggregate offering price of its at-the-market common stock program to $53,398,964 under its Sales Agreement with H.C. Wainwright & Co.
This includes an additional $36,800,000 of capacity, on top of approximately $21,257,000 of common stock already sold under the agreement, and is supported by a new prospectus supplement and related legal opinion filed as an exhibit.
ADTX amends its shelf to increase its ATM capacity to $53,398,964. This prospectus supplement adds $36,800,000 of new ATM capacity, bringing the aggregate authorized amount under the sales agreement to $53,398,964, and leaves prior terms and the sales agreement unchanged.
The supplement states the company has previously sold approximately 398,950 shares for aggregate gross proceeds of $21,257,000, leaving about $16,500,000 of prior capacity before this increase. The filing also discloses the last reported Nasdaq sale price of the common stock was $0.81 per share as of March 27, 2026.
Aditxt, Inc. is soliciting proxies for its 2026 Annual Meeting to be held in a virtual-only format at www.virtualshareholdermeeting.com/ADTX2026. Stockholders of record as of the board‑fixed [RECORD DATE], 2026 may vote on six proposals.
The six proposals include: (1) election of five director nominees (the board will be reduced to five following the meeting), (2) ratification of dbbmckennon as auditor, (3) an advisory "say-on-pay" vote, (4) an advisory vote on say-on-pay frequency (the board recommends EVERY 3 YEARS), (5) authorization to permit the board to effect a reverse stock split within one year at a ratio the board may set within a disclosed range, and (6) authorization to adjourn the meeting if needed. The proxy materials and the 2025 Annual Report on Form 10-K are available at www.proxyvote.com.
Aditxt, Inc. entered into a definitive agreement to acquire Ignite Proteomics, LLC, obtaining 100% of Ignite’s equity plus $475,000 in cash in exchange for 36,000 shares of newly created Series A-2 Convertible Preferred Stock with an aggregate stated value of $36,000,000.
The preferred shares convert into common stock at a Conversion Price of $2.731 per share, subject to adjustments and a 9.99% beneficial ownership cap, and may be redeemed by Aditxt at 100% of the conversion amount. On March 11, 2026, Aditxt also issued 10% original issue discount promissory notes with aggregate principal of $3,194,444.44, providing $2,875,000 in funding at 6% annual interest (rising to 12% on default) and maturing nine months after issuance.
The company believes the Ignite transaction has increased its stockholders’ equity above $2.5 million, which would bring it back into compliance with Nasdaq’s stockholders’ equity listing requirement, and is awaiting Nasdaq’s formal confirmation.